Evidence map›Paper›PMID 36545559›Full record

ArticleClinical case reports2022

Ciprofloxacin induced toxic epidermal necrolysis with cholestatic hepatitis: A case report with literature review and revisit to the Naranjo adverse drug reaction probability scale.

Bishal Dhakal, Sagun Dawadi, Laxman Khadka, Sujan Bohara, Shashank Neupane, Priajan Ale Magar, Bishnu Deep Pathak, Binit Upadhaya Regmi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Severe tolvaptan-associated hyperglycemia: a case report.Journal of medical case reports · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Bishal DhakalNepalese Army Institute of Health Sciences, Sanobharyang Kathmandu Nepal.ORCID https://orcid.org/0000-0001-9432-5233
Sagun DawadiNepalese Army Institute of Health Sciences, Sanobharyang Kathmandu Nepal.ORCID https://orcid.org/0000-0001-9352-4847
Laxman KhadkaPatan Academy of Health Sciences Kathmandu Nepal.
Sujan BoharaMediciti Hospital Lalitpur Nepal.ORCID https://orcid.org/0000-0003-3056-5283
Shashank NeupaneNepalese Army Institute of Health Sciences, Sanobharyang Kathmandu Nepal.ORCID https://orcid.org/0000-0001-5339-8962
Priajan Ale MagarNepalese Army Institute of Health Sciences, Sanobharyang Kathmandu Nepal.
Bishnu Deep PathakJibjibe Primary Health Care Center Rasuwa Nepal.ORCID https://orcid.org/0000-0002-0811-8316
Binit Upadhaya RegmiJibjibe Primary Health Care Center Rasuwa Nepal.
Nepalese Army Institute of Health Services · NPPrimary Health Care · QANepal Cancer Hospital and Research Center · NPPatan Academy of Health Sciences · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ciprofloxacin, among the many Fluoroquinolones, has been widely used as a broad-spectrum antibiotic due to its wide range of action and relatively safe adverse effect profile. However, among the cutaneous adverse drug reactions due to Ciprofloxacin, toxic epidermal necrolysis occurring along with cholestatic hepatitis is a rare one. Here, we present a case of a 22-year-old male patient who was diagnosed with toxic epidermal necrolysis with cholestatic hepatitis secondary to Ciprofloxacin. Naranjo adverse drug reaction probability scale was used for the causal association.

Indexed as

adverse drug reactioncholestatic hepatitisciprofloxacinNaranjo scaletoxic epidermal necrolysis

Identifiers

PMID36545559
PMCPMC9764033
OpenAlexW4312086033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.